Although the upregulation of all CCT components showed a stronger ability to predict poor outcomes in breast cancer patients who received systemic postoperative chemotherapy than in unclassified and untreated patients, multivariate analysis revealed that CCT-β, among all CCT components, was the most useful indicator for predicting a poor chemotherapeutic response (Figure 1A). This evidence concerns the gene FLVCR2 and breast carcinoma.